HITLAB is proud to announce that Divya Verma has joined the Breakthrough Alliance as a Global Fellow, bringing more than a decade of expertise in pharmaceutical innovation, global commercialization, and healthcare strategy to our growing network of thought leaders driving digital health transformation.

Divya’s introduction to HITLAB came through a personal connection—her husband was one of Dr. Stan Kachnowski’s students at the Indian Institute of Technology (IIT) Delhi, the same institution where Stan has been inspiring innovators for years. This connection sparked Divya’s interest in HITLAB’s mission to advance digital health through evidence-based research and collaboration.

Divya began her career in investment banking at Lehman Brothers, building a strong foundation in finance and strategic planning before transitioning into the pharmaceutical industry. Over the past 11+ years, she has led global product launches, portfolio strategies, and commercialization initiatives across branded and generic markets, delivering $800M+ in launch revenue and shaping go-to-market strategies for innovative therapies.

Most recently, as Vice President of Marketing & Portfolio at Accord Healthcare, a global leader with $2.5B in revenue, Divya launched 13 products in 12 months, exceeding revenue targets and expanding the U.S. pipeline by adding high value assets. She currently serves as Vice President, Business Development at Accord Healthcare, where she focuses on near-term growth and U.S. market expansion. Her previous leadership roles at American Regent, Fosun Pharma, Azurity Pharmaceuticals, and Sun Pharma further highlight her impact on healthcare innovation, including the successful launch of First-to-File Imatinib® (Gleevec) at Sun Pharma, generating over a half a billion in revenue (IQVIA) in six months.

Her previous leadership roles at American Regent, Fosun Pharma, Azurity Pharmaceuticals, and Sun Pharma further highlight her impact on healthcare innovation, including the successful launch of First-to-File Imatinib® (Gleevec) at Sun Pharma, generating $550M in six months.

Holding an MBA in Marketing and Finance from IE Business School, Divya brings a global perspective on health technology, commercialization, and patient access strategies. She is passionate about patient-focused solutions that improve access, affordability, and adherence.

At HITLAB, Divya will leverage her expertise to support digital health innovators, guide strategic partnerships, and advance the mission of the Breakthrough Alliance: accelerating healthcare innovation through evidence-based research and collaboration.

Please join us in welcoming Divya Verma to the HITLAB community!